Arcturus Therapeutics Stock Price, Forecast & Analysis (NASDAQ:ARCT)

Arcturus Therapeutics trades on the NASDAQ under the ticker symbol "ARCT."

Arcturus Therapeutics Ltd (NASDAQ:ARCT) released its quarterly earnings results on Thursday, August, 15th. The biotechnology company reported ($0.07) EPS for the quarter, beating the consensus estimate of ($0.53) by $0.46. The biotechnology company earned $10.15 million during the quarter, compared to the consensus estimate of $4.01 million. Arcturus Therapeutics had a negative net margin of 63.05% and a negative return on equity of 160.16%. View Arcturus Therapeutics' Earnings History.

Arcturus Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, March 16th 2020. View Earnings Estimates for Arcturus Therapeutics.

5 equities research analysts have issued 1-year price objectives for Arcturus Therapeutics' shares. Their forecasts range from $18.00 to $18.00. On average, they anticipate Arcturus Therapeutics' share price to reach $18.00 in the next year. This suggests a possible upside of 74.8% from the stock's current price. View Analyst Price Targets for Arcturus Therapeutics.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Arcturus Therapeutics in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Arcturus Therapeutics.

Press coverage about ARCT stock has been trending very negative on Wednesday, InfoTrie Sentiment Analysis reports. InfoTrie identifies negative and positive press coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Arcturus Therapeutics earned a news sentiment score of -3.2 on InfoTrie's scale. They also gave media stories about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the stock's share price in the near future. View News Stories for Arcturus Therapeutics.

Arcturus Therapeutics saw a increase in short interest in October. As of October 31st, there was short interest totalling 103,900 shares, an increase of 35.3% from the September 30th total of 76,800 shares. Based on an average trading volume of 92,100 shares, the days-to-cover ratio is currently 1.1 days. Approximately 1.5% of the shares of the stock are short sold. View Arcturus Therapeutics' Current Options Chain.

Some companies that are related to Arcturus Therapeutics include Retrophin (RTRX), Intra-Cellular Therapies (ITCI), Myovant Sciences (MYOV), Catalyst Pharmaceuticals (CPRX), Progenics Pharmaceuticals (PGNX), Synthorx (THOR), BioDelivery Sciences International (BDSI), Homology Medicines (FIXX), ImmunoGen (IMGN), Aprea Therapeutics (APRE), Advanz Pharma (CXRXF), Urogen Pharma (URGN), Aurinia Pharmaceuticals (AUPH), Cytokinetics (CYTK) and Akebia Therapeutics (AKBA).

Based on aggregate information from My MarketBeat watchlists, some companies that other Arcturus Therapeutics investors own include Opko Health (OPK), Terravia (TVIAQ), KLA-Tencor (KLAC), Energy Transfer LP Unit (ET), Obsidian Energy (OBE), Corbus Pharmaceuticals (CRBP), Amicus Therapeutics (FOLD), Inovio Pharmaceuticals (INO), Rexahn Pharmaceuticals (REXN) and NovaBay Pharmaceuticals (NBY).

Arcturus Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional investors include Dfpg Investments Inc. (3.23%), Sumitomo Mitsui Trust Holdings Inc. (2.09%), Nikko Asset Management Americas Inc. (2.09%) and We Are One Seven LLC (0.10%). Company insiders that own Arcturus Therapeutics stock include Andy Sassine, Joseph E Payne, Magda Marquet and Peter C Farrell. View Institutional Ownership Trends for Arcturus Therapeutics.

ARCT stock was acquired by a variety of institutional investors in the last quarter, including Dfpg Investments Inc., Sumitomo Mitsui Trust Holdings Inc., Nikko Asset Management Americas Inc. and We Are One Seven LLC. Company insiders that have bought Arcturus Therapeutics stock in the last two years include Andy Sassine, Joseph E Payne, Magda Marquet and Peter C Farrell. View Insider Buying and Selling for Arcturus Therapeutics.

Shares of ARCT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of ARCT stock can currently be purchased for approximately $10.30.

Arcturus Therapeutics has a market capitalization of $147.03 million and generates $15.75 million in revenue each year. The biotechnology company earns $-21,780,000.00 in net income (profit) each year or ($2.16) on an earnings per share basis. Arcturus Therapeutics employs 72 workers across the globe.View Additional Information About Arcturus Therapeutics.

The official website for Arcturus Therapeutics is http://www.arcturusrx.com/.

Arcturus Therapeutics' mailing address is 10628 SCIENCE CENTER DRIVE SUITE 200, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at 858-900-2660 or via email at [email protected]